Regeneron Pharmaceuticals

REGN Net selling

CIK 0000872589 #390 in the set updated 17 Sep 2026

Bought (120 mo)

$212.20M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$13.65B

$243.79M on a plan · $433.34M straight out of an exercise

Sold at will

$12.98B

1347 of 2403 sales

Net

−$13.44B

−$12.76B against sales at will

By person

27 insiders · 2,660 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Sanofi

10% owner

$212.20M (61)

$11.95B (8)

−$11.74B

279,766

0.272%

$239.87M

−98.8%

YANCOPOULOS GEORGE

Bd. Co-Chair, President & CSO

—

$350.69M (90)

−$350.69M

366,508

0.357%

$314.24M

+11.0%

SCHLEIFER LEONARD S

Bd. Co-Chair, President & CEO

—

$319.83M (61)

−$319.83M

214,523

0.209%

$183.93M

—

VAGELOS P ROY

Director

—

$248.68M (100)

−$248.68M

438,071

0.426%

$375.60M

−33.5%

SING GEORGE L

Director

—

$115.92M (116) scheduled

−$115.92M

32,007

0.031%

$27.44M

−75.2%

Van Plew Daniel P

EVP & General Mgr, Industrial

—

$91.86M (117)

−$91.86M

21,673

0.021%

$18.58M

—

STAHL NEIL

EVP Research and Development

—

$81.55M (138)

−$81.55M

53,434

0.052%

$45.81M

+14.1%

POON CHRISTINE A

Director

—

$70.50M (37) scheduled

−$70.50M

5,219

0.005%

$4.47M

+560.6%

MURPHY ANDREW J

EVP Research

—

$57.65M (209)

−$57.65M

47,833

0.047%

$41.01M

+5.5%

Tessier-Lavigne Marc

Director

—

$45.88M (44) scheduled

−$45.88M

2,434

0.002%

$2.09M

+138.2%

BROWN MICHAEL S

Director

—

$44.70M (84) scheduled

−$44.70M

7,865

0.008%

$6.74M

−36.3%

GOLDSTEIN JOSEPH L

Director

—

$44.70M (69) scheduled

−$44.70M

6,703

0.007%

$5.75M

−48.4%

RYAN ARTHUR F

Director

—

$38.85M (698) scheduled

−$38.85M

17,303

0.017%

$14.84M

−50.6%

LAROSA JOSEPH J

EVP General Counsel and Secret

—

$34.69M (81)

−$34.69M

36,373

0.035%

$31.19M

+1,111%

McCourt Marion

EVP Commercial

—

$32.98M (52) scheduled

−$32.98M

12,222

0.012%

$10.48M

+5,481%

Fenimore Christopher R.

EVP Finance CFO

—

$30.33M (84)

−$30.33M

20,009

0.019%

$17.16M

—

Bassler Bonnie L

Director

—

$22.33M (26) scheduled

−$22.33M

1,703

0.002%

$1.46M

—

Landry Robert E

EVP Finance CFO

—

$20.88M (288)

−$20.88M

23,693

0.023%

$20.31M

+233.8%

COLES N ANTHONY

Director

—

$20.62M (33) scheduled

−$20.62M

1,714

0.002%

$1.47M

—

Zoghbi Huda Y

Director

—

$11.89M (34) scheduled

−$11.89M

1,703

0.002%

$1.46M

—

Terifay Robert J

EVP Commercial

—

$9.90M (1)

−$9.90M

25,214

0.025%

$21.62M

+8.2%

Pitofsky Jason

SVP Controller

—

$2.39M (13) scheduled

−$2.39M

4,451

0.004%

$3.82M

+5.9%

BAKER CHARLES A

Director

—

$2.08M (6) scheduled

−$2.08M

9,000

0.009%

$7.72M

0.0%

Aberman Michael S

SVP Strategy Investor Relation

—

$1.21M (12)

−$1.21M

4,693

0.005%

$4.02M

0.0%

Guarini Kathryn

Director

—

$660.00K (2) scheduled

−$660.00K

603

<0.001%

$517.01K

—

Thompson Craig B.

Director

—

—

—

775

<0.001%

$664.48K

—

Schenkein David P

Director

—

—

—

603

<0.001%

$517.01K

—

Individual transactions

0

Nothing of that kind in this period.

What was left out

Form 4 filings counted 671

Amendments (4/A) skipped 1

Filings about a different issuer 1

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 462

Sales straight out of an exercise 594

Sales at will 1,347

Transactions with no price 0

Shares from compensation/vesting 22,075,148

Sales filed before the plan box existed 1,292

History held since 2 Sep 2016